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Abstract
Introduction: The extraordinary feat of proving the effectiveness of oral pre-exposure prophylaxis (PrEP) in clinical trials in
different populations in a variety of settings may prove to have been easier than ensuring it is used well. Decision-makers must
make difficult choices to realize the promise of antiretroviral prophylaxis for their countries. This paper outlines key economic,
regulatory and distributive justice issues that must be addressed for effective and acceptable PrEP implementation.
Discussion: In considering the role that PrEP can play in combination prevention programmes, decision-makers must determine
who can benefit most from PrEP, how PrEP can be provided safely and efficiently, and what kind of health system support will
ensure successful implementation. To do this, they need contextualized information on disease burden by population, analyses
of how PrEP services might best be delivered, and projections of the human resource and infrastructure requirements for each
potential delivery model. There are cost considerations, varying cost-effectiveness results and regulatory challenges. The
principles of ethics can inform thorny discussions about who should be prioritized for oral PrEP and how best to introduce it
fairly. We describe the cost-effectiveness of PrEP in different populations at higher risk of HIV exposure, its price in low- and
middle-income countries, and the current regulatory situation. We explore the principles of ethics that can inform resource
allocation decision-making about PrEP anchored in distributive justice, at a time when universal access to antiretroviral
treatment remains to be assured. We then highlight the role of advocacy in moving the PrEP agenda forward.
Conclusions: The time is ripe now for decisions about whether, how and for whom PrEP should be introduced into a country’s
HIV response. It has the potential to contribute significantly to high impact HIV prevention if it is tailored to those who can most
benefit from it and if current regulatory and pricing barriers can be overcome. Advocacy at all levels can help inform decision-
making and push the access agenda to avert HIV infections among those at highest risk of HIV exposure. The benefits will accrue
beyond the individual level to slow HIV transmission at the population level.
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Introduction
In clinical trials conducted in Africa, Asia, Europe and North
America over the past decade, pre-exposure prophylaxis (PrEP),
using oral formulations of the antiretroviral drugs tenofovir
or tenofovir/emtricitabine (TDF/FTC), has been shown to
significantly reduce the risk of HIV acquisition among men
who have sex with men (MSM) [13], heterosexual men and
women [4,5], and people who inject drugs (PWID) [6]. Trials
involving monthly insertion of a vaginal ring containing the
antiretroviral dapivirine will report results in 2016 [7,8].
Following good safety signals [9], long-acting PrEP is currently
being investigated in trials of injectable rilpivirine [10] and
cabotegravir [11].
With vaginal rings and injectables potentially coming on
the heels of proven oral PrEP, it is important to consider
how best to introduce these new options into current HIV
combination prevention strategies [12,13] to achieve reduc-
tions in HIV risk at individual and community levels. Thus far,
a daily oral PrEP product, TDF/FTC (Truvada†), has been
approved for use but only in the United States [14]. This
US Food and Drug Administration (FDA) regulatory approval
in July 2012 was quickly followed by initial World Health
Organization (WHO) guidelines for the conduct of PrEP de-
monstration projects [15]. More recently, WHO has issued
additional guidance for key populations [16].
A large number of demonstration projects are now under-
way in trial-naı¨ve populations [17], complementing the post-
trial access studies among participants of the original trials
reporting efficacy. In addition, the Partners PrEP trial rando-
mized participants in the former placebo arm to either TDF/
FTC or tenofovir alone, since both products reduced HIV
acquisition risk, and found that the lower-cost single drug
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also provides high protection [18]. This suite of projects
and studies is providing valuable data to inform country
implementation strategies.
Decision-makers, faced with the results of a plethora of
studies in diverse populations and regulatory approval for
oral PrEP only in the United States, have difficult choices to
make to realize the promise of antiretroviral prophylaxis [19]
for their countries. They need contextualized information
on disease burden by population, analyses of how PrEP ser-
vices might best be delivered, and assessment of the human
resource and infrastructure requirements for potential deli-
very models. There are cost considerations, varying cost-
effectiveness results, regulatory challenges and ethical concerns
that must be addressed to ensure that oral PrEP is a tangible
HIV prevention choice for those individuals who can most
benefit from it. Complementing other papers in this supple-
ment addressing PrEP, this paper outlines key economic,
regulatory, distributive justice, and access issues that must
be addressed in each context to realize the full potential of
effective and acceptable PrEP implementation.
Discussion
Cost-effectiveness, pricing and trade-offs
Cost-effectiveness
Cost-effectiveness analysis is a standard method used for
allocating resources in health policy. It seeks to determine
how the most effective policy can be implemented at the
least cost. Studies of oral PrEP cost-effectiveness have used a
variety of metrics, estimating cost per HIV infection aver-
ted [2022], cost per quality-adjusted life year (QALY) gained
[21,2327], cost per disability-adjusted life year (DALY) aver-
ted [28], cost per year life saved [29] and PrEP years
per infection averted [30]. The studies have examined PrEP
for heterosexual transmission in southern Africa [20] and
South Africa [21,22,29,3133] and for other modes of trans-
mission, among PWID in Ukraine [25] and MSM in the USA
[23,24,26,27] and Peru [28].
A systematic review of 13 cost-effectiveness studies found that
key considerations to address in assessing cost-effectiveness
of PrEP are cost, epidemic context, individual adherence level,
PrEP programme coverage and prioritization strategy [34].
PrEP could be a potentially cost-effective addition to HIV-
prevention programmes, particularly when those at highest
risk of HIV exposure are prioritized, although drug costs
would limit cost-effectiveness. While PrEP could have impact
in key populations such as MSM, the first priority for PWID
might be expanding access to antiretroviral treatment (ART)
and opioid substitution therapy. In considering trade-offs,
prioritizing PrEP for young women in southern Africa who
are at alarmingly high risk of HIV acquisition can be cost-
effective, especially when there are costly obstacles to
recruiting HIV-positive people for treatment using the same
drug [35].
Cost-effectiveness studies guide resource allocation deci-
sions by indicating where resources can be applied for
greatest impact. Funding PrEP while other potentially more
cost-effective HIV prevention interventions remain under-
funded may have high opportunity costs, diverting resources
from early ART initiation or other prevention strategies [34].
It is therefore important, as oral PrEP moves into demonstra-
tion projects and regular use in some settings, to obtain and
integrate real-world costing data for all PrEP programme
elements to replace earlier hypothetical costs. This will assist
policy-makers in planning future resource allocations for PrEP
as part of high-impact combination prevention.
Pricing
The price of drugs is a key component of overall programme
costing. The price of tenofovir-containing ART regimens from
originator sources has remained static since 2007, while the
lowest prices of stand-alone tenofovir fell by almost half in 12
months, from $48 per person year in 2013 to $26 in 2014 [36].
In 2012, it was estimated that over half of all people on ART in
countries with generic access were on tenofovir-based regi-
mens, with this proportion estimated to rise to 70% of patients
on first-line treatment regimens by the end of 2014 [36].
Trade-offs
Paying for tenofovir-based PrEP when access to ART is not
universal is an issue that requires careful reflection in each
context. People who do not acquire HIV because of the effec-
tive use of PrEP when they are at most risk of HIV acquisition
will avoid lifelong ART and its associated costs.
Drugs that are not used for ART, such as maraviroc, which
is currently being assessed in the Next-PrEP clinical trial [37],
would not present direct competition for drug use, but the
overall issue of resource allocation remains. The dapivirine
vaginal ring, replaced monthly, is being assessed in two Phase
III trials [7,8]. Phase I trials of the long-acting injectables, bi-
monthly rilpivirine (TMC 278), a non-nuclease reverse trans-
criptase inhibitor [38], and tri-monthly cabotegravir (S/
GSK1265744), an integrase inhibitor [39], have reported
safety and tolerability [9] with Phase II trials following suit
[10,11]. Thus, the potential array of delivery options could
expand to provide choices for PrEP that would not necessa-
rily compete with treatment drug demands. Issues of cost,
access, equity and trade-offs will remain. However, without
regulatory approval no PrEP option can be rolled out where it
is most needed.
Regulatory issues
Following FDA approval of oral TDF/FTC for a prevention
indication, its manufacturer Gilead Sciences, Inc. applied for
approval in 4 of the 14 countries that hosted TDF/FTC PrEP
trials: South Africa (December 2013), Thailand (April 2014),
and Australia and Brazil (late 2014). Figure 1 outlines the
countries in which PrEP trials have taken place and the
current status of regulatory review for a prevention indica-
tion of oral TDF/FTC [40].
It is unclear when the four pending applications will be
decided and when the company might apply in the other
host trial countries. The drug has been registered for HIV
treatment in 154 countries worldwide, including 110 low-
and middle-income countries [41]. It is available as Gilead-
branded Truvada† or as generic versions in developing countries
through Gilead’s partnerships with generic manufacturers.
Gilead Sciences was the first pharmaceutical company to
commit to the Medicines Patent Pool, a United Nations-
backed organization established in 2010 to improve access to
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appropriate, affordable HIV medicines and technologies for
people living with HIV in developing countries, and recently
signed a licence for the new medicine tenofovir alafenamide
(TAF) [42].
Thus, while TDF/FTC is already available in many countries
as an approved therapeutic, the absence of a prevention
indication outside the United States limits programmatic and
policy decisions to expand access to PrEP. However, recent
clinical trial developments may move TDF/FTC onto a faster
track for regulatory approval. The PROUD trial of daily oral
PrEP in England was unblinded in October 2014 on the re-
commendation of its Data Safety Monitoring Board when it
became no longer ethical, in light of the compelling findings,
to continue the delayed arm that had no access for 12
months [43]. Two weeks later, the IPERGAY trial of event-
driven PrEP (2 pills before sex and 1 pill 24 h and 48 h later)
in France and Canada was unblinded and its placebo arm
offered PrEP [44]. PROUD found that PrEP reduced HIV risk
by 86% (90% CI: 58;98) compared with no-PrEP (p0.0002)
[2], while Ipergay also reported an 86% reduction in HIV
incidence (95% CI: 40;99), p0.002 [3]. Gilead Sciences is
considering submission to the European Medicines Agency
(EMA) for regulatory approval, which would expand access in
Europe. However, EMA regulatory approval for low- and
middle-income countries can only be done for medicinal
products for human use that are intended exclusively for
markets outside the European Union [45].
Ethical considerations
Principles of distributive justice
While cost-effectiveness analysis seeks to determine how
the most effective policy can be implemented at the least
cost, the result may conflict with the application of ethical
principles designed to introduce important values other than
monetary ones. Examining leading principles of justice can
identify different priorities for allocation of PrEP although
the principles can conflict, requiring a balance of competing
concerns. There is no uniquely correct way of doing this
balancing. Furthermore, there is no consensus on what weight
to give to the different principles [46]. It has even been
argued that the impossibility of achieving a consensus on
which principle to choose requires abandoning the search for
substantive principles of justice and instead, introducing
a method that involves fairness in the procedural aspects
of allocation decision-making [47]. However, procedural fair-
ness does not guarantee fairness as an outcome that would
accord with any of the leading substantive principles of
distributive justice.
The principle of utility [48,49] is the one most widely used
in health policy: choose the option that has the most bene-
ficial consequences and the fewest harmful consequences for
society as a whole. The philosophical and economic literature
contains numerous versions of utilitarian theory. A general
form of consequentialist utility theory, known as Total Conseq-
uentialism, indicates that ‘‘. . . moral rightness depends only
on the total net good in the consequences (as opposed to
the average net good per person)’’ [50]. Applying this prin-
ciple requires specifying which consequences are to count:
minimizing costs, preventing new infections or ensuring
fairness in the distribution of PrEP. It is evident that the
utilitarian principle can yield different results depending on
an array of empirical facts and circumstances.
Two principles that are sometimes conflated are the ega-
litarian principle [49] and the principle of equity [51,52].
Whereas the egalitarian principle mandates treating all in
need equally, the principle of equity allows for contextual
factors to be considered in a fair distribution of resources.
When deciding which groups should receive PrEP first as pre-
vention programmes are scaled up, decision-makers should
consider whether all in need should be treated equally or
whether certain groups, such as those who are marginalized,
stigmatized or typically underserved, should be given pre-
ference. A well-known application of the egalitarian principle
is a lottery among the pool of potential users when supplies
are limited. Egalitarian principles make no distinctions re-
garding who might benefit most from an intervention or
what choice would best serve the goals of public health. The
principle of equity has a specific meaning in the context of
Figure 1. Regulatory approval in trial host countries for daily TFD/FTC.
Permission to use granted by AVAC.
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access to health care: ‘‘The dominant conceptualization of
equitable access to health care among health service re-
searchers builds on the idea that the utilization of services
should reflect actual needs for care’’ [53]. Application of this
principle to PrEP might focus on traditionally underserved popu-
lations, as well as on young women at high risk of infection
because poverty, misogyny and their limited social capital
make them less able than others to avoid unprotected sex.
The prioritarian principle [54] calls for ensuring that re-
sources are provided to the least-advantaged members or
groups in society. In the context of HIV prevention, these might
be those at greatest risk of becoming infected, the poorest
people, the most vulnerable or the most highly stigmatized.
It is clear that applying principles of distributive justice for
making health care allocations cannot guarantee justice in
outcomes. They are designed for selecting populations to
be given priority in a particular context, with the principle
of equity designed to eliminate socio-economic and other
barriers to care.
Allocating resources for HIV prevention
Because resources for PrEP are insufficient to meet the needs
of all who could benefit, decisions are needed about which
populations should be given priority for receiving PrEP.
People who engage in behaviour that places them at higher
risk of HIV acquisition and whose sexual networks likely
extend beyond their own subpopulation are an obvious
choice because they have the greatest likelihood of transmit-
ting HIV if they acquire it. Providing them with access to
antiretroviral prevention first may mean that HIV infection
will spread more slowly in a country. Thus, a logical choice as
early priority populations for receiving PrEP could be young
women, sex workers, MSM and PWID; however, these may
be among the hardest people to reach.
The prioritarian principle operates as a constraint on the
utilitarian principle to ensure that the most disadvantaged
individuals are not ignored in the effort to scale up HIV
prevention [46]. Different criteria exist for determining who
are the most disadvantaged. Populations already identified as
early priorities for HIV prevention according to the utilitarian
principle appear also to be among the least advantaged accord-
ing to several criteria. In most societies, they are stigmatized,
marginalized, and typically engaged in illegal behaviour, and
are often at greater risk from authorities. This includes PWID
in countries with punitive drug policies, MSM in some African
countries where homosexual behaviour is a criminal offense
and sex workers in most countries worldwide. Thus, the
utilitarian and prioritarian principles concur that those
who are most at risk of HIV exposure should be the first to
receive PrEP.
The fastest growing group of newly infected people in sub-
Saharan Africa is young women. According to UNAIDS, ‘‘In
sub-Saharan Africa, women and girls account for almost 57%
of adults living with HIV. Recent surveys reveal that in South
Africa, Zambia, and Zimbabwe, young women (age 1524)
are five to six times more likely to be infected than young
men of the same age’’ [55]. The principle of equity might,
therefore, call for scaling up HIV testing and offering PrEP to
young HIV-negative women who are likely to be at risk.
Finally, HIV serodiscordant couples might be prioritized
for PrEP, when the HIV-positive partner, whether on ART or
not, is not virally supressed. A 96% reduction in HIV-negative
partners’ risk of HIV acquisition was recently reported in a
study of HIV-serodiscordant couples offered immediate ART
for the HIV-positive partner and PrEP for the HIV-negative
partner [56]. According to the principle of urgent need [57],
HIV-negative partners in serodiscordant couples where the
HIV-positive partner is not virally suppressed would have
priority for PrEP because they risk acquiring HIV with each
sexual act.
The urgent need principle can be combined with the
utilitarian principle in setting priorities for allocating PrEP,
with the principle of equity giving priority to stigmatized and
marginalized populations, such as MSM, sex workers and
PWID, and young women and serodiscordant couples.
Advocacy for access
Since the early PrEP trial controversies [58,59], advocates
have played an active role in monitoring trials, interpreting
trial results, advocating for access, disseminating information
and, in the United States, engaging in the regulatory process.
Shortly after several of the first oral PrEP trials were
stopped in 2005 amidst controversy, AVAC and UNAIDS began
a consultative process with civil society representatives,
researchers and funders to develop approaches to guide pro-
ductive engagement in research. The resulting Good Partici-
patory Practice Guidelines [60] are now increasingly used
across a range of HIV prevention trials and have been adapted
for use in non-HIV research efforts [61].
Following the iPrEx trial results in 2010 [1], a number of
advocacy groups played leading roles in their countries and
communities to explain clinical trial results and push for
evidence-based policies and programmes. A coalition of 14
US HIV and health advocacy organizations submitted exten-
sive public comments to the FDA in 2012 to support approval
of TDF/FTC as PrEP. Their written comments, as well as formal
presentations at the public FDA Advisory Committee meeting,
pointed to the compelling evidence on the efficacy of PrEP
and highlighted the unique potential of this intervention [62].
Advocacy groups, representing diverse populations who
need and could most benefit from PrEP, especially in countries
where the PrEP trials took place, also called for an ambitious,
well-coordinated scale-up of demonstration projects across
diverse populations of men, women and transgender people
at risk for HIV through sex [63,64]. For example, the US
Women and PrEP Working Group, a coalition of women from
leading AIDS and women’s health organizations, advocates for
a national agenda to answer questions about the best way to
make PrEP available to women as a prevention option.
Finally, web-based community efforts include AVAC’s PrEP
Watch website (www.prepwatch.org), a clearinghouse for
information on PrEP, and the AIDS Foundation of Chicago’s My
PrEP Experience (www.myprepexperience.blogspot.com), fea-
turing stories from people who have chosen to use PrEP.
Conclusions
Decision-makers considering the introduction of PrEP in their
countries are faced with competing priorities and the need to
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address key economic, regulatory, distributive justice and
access issues. Unless these processes are informed by inputs
relative to their own specific context, it will be difficult to
realize the full potential of effective and acceptable PrEP
implementation. Using disease burden, costing information
and known effectiveness, cost-effectiveness studies that illus-
trate the utilitarian principle at work can provide an initial
indication of the potential impact of PrEP programmes. The
results may conflict with the application of egalitarian or
prioritarian principles of distributive justice.
The price of PrEP varies widely and the US FDA is the only
regulatory agency to approve it for HIV prevention thus far.
This approval has helped pave the way for greater access and
insurance reimbursement for PrEP in the United States, but
even there access challenges remain for some seeking PrEP.
Although the regulatory pathway in Europe seems clearer in
light of the recent European trial results, answers will be
needed to the question of who will pay. Countries that lack
regulatory capacity to independently evaluate the use of TDF/
FTC as PrEP might use WHO pre-qualification and guidance,
when available. The question of who will pay for PrEP in low-
and middle-income countries requires frank discussions at
national level and with international donors supporting
strategies to end AIDS. These will need to be underpinned
by discussions of equity and ethical allocation under condi-
tions of limited resources.
Transitioning from clinical trial efficacy to public health
impact is never easy. Experiences with preventing vertical
transmission, programming the female condom, providing
post-exposure prophylaxis (PEP), delivering sterile needles
and scaling up voluntary medical male circumcision, amongst
others, provide cogent examples in HIV prevention of slow
policy and programme responses, unrealized expectations
and resultant limited impact. There are important lessons to
be learned about the factors that facilitate and impede
uptake of new HIV prevention innovations [65].
PrEP is not meant for everyone, all of the time. If done
well, though, initial PrEP introduction activities will enable
policy-makers and programme planners to answer the ques-
tions of who can benefit most from PrEP, how to provide it
safely and efficiently, how to integrate PrEP into combina-
tion treatment and prevention programmes, and what kind
of health system support is needed to ensure successful
implementation.
The extraordinary feat of proving PrEP’s efficacy may turn
out to have been easier than ensuring that it is used well.
This is not unique to PrEP and insights can be gleaned from
experiences with implementation of other novel strategies.
Ensuring that PrEP fulfils its potential as part of high-impact
combination HIV prevention requires establishing the addi-
tional evidence, education, support services and resources
that are needed, as well as the regulatory framework and
cost scenarios for access to PrEP.
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